Biotech firm BioAtlantis secures €750,000 investment

BioAtlantis is involved in the research, development and manufacture of plant biostimulants and animal prebiotics using molecules derived from seaweeds, with scope for future development of human nutraceuticals.

 

The company’s lead products are biostimulants and GutCare. Biostimulants are used for promoting plant health and growth and BioAtlantis markets its biostimulant range of products in over 22 countries.

 

According to the firm, an EU-wide ban on the use of growth-promoting antibiotics in animal feed has created a market for its GutCare product, which has been developed as an alternative to antibiotics in intensively farmed post-weaned piglets.

 

GutCare trials are also expected to commence later this year in the poultry industry.

 

CEO John O’ Sullivan said: “The funding provided by the Bank of Ireland Kernel Capital Fund will allow for further research and investment in processing equipment that will bring GutCare and potential human applications to the market over the next two years.”